The company developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that generated a pipeline of wholly-owned and partnered product candidates with potential to treat a range of cancers. The company had strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates.
Cyborg Score Rationale
Mersana demonstrated scientific merit with innovative ADC platforms and industry partnerships, but remained early-stage with Phase 1 clinical programs. The acquisition by Day One suggests limited independent value but validates the potential of its lead program Emi-Le in rare oncology.
Top Insights
Day One Biopharmaceuticals completed acquisition of Mersana Therapeutics in January 2026
Acquisition valued at approximately $285 million total deal value including upfront cash of $25 per share and contingent value rights of up to $30.25 per share
Pipeline included Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting HER2
Q3 2025 showed collaboration revenue of $11.0 million and net loss of $7.5 million
Named Competitors
Sutro Biopharma — ADC-focused biotech with protein design platform
CytomX Therapeutics — Probody ADC technology platform for oncology
MacroGenics — Immunotherapeutic and ADC pipeline for cancer
Recent Developments
(January 2026) Day One Biopharmaceuticals completes acquisition; MRSN delists from Nasdaq
(November 2025) Definitive merger agreement announced by Day One Biopharmaceuticals
(Q3 2025) Reported $11.0 million in collaboration revenue with $7.5 million net loss
Open the full interactive Mersana Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.